[go: up one dir, main page]

WO1999055881A1 - Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it - Google Patents

Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it Download PDF

Info

Publication number
WO1999055881A1
WO1999055881A1 PCT/KR1998/000487 KR9800487W WO9955881A1 WO 1999055881 A1 WO1999055881 A1 WO 1999055881A1 KR 9800487 W KR9800487 W KR 9800487W WO 9955881 A1 WO9955881 A1 WO 9955881A1
Authority
WO
WIPO (PCT)
Prior art keywords
cephalosporin
strain
enzyme
deacetylase
bacillus
Prior art date
Application number
PCT/KR1998/000487
Other languages
French (fr)
Inventor
Yong Duk Kim
Il Seon Jeong
Sang Hoon Lee
Duk Ho Choi
Kum Soo Han
Bun Sam Lim
Original Assignee
Daesang Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daesang Corporation filed Critical Daesang Corporation
Publication of WO1999055881A1 publication Critical patent/WO1999055881A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin

Definitions

  • the present invention relates to a new enzyme, a gene coding for it and its use to produce cephalosporin compounds. More particularly, it relates to a new cephalosporin deacetylase, a gene coding for it, and its use to deacetylate cephalosporin C, 7-aminocephalosporanic acid (7-ACA) and 2-memoxyirnino-2- furylacetic cephalosporanic acid (MIFACA) to produce cephalosporin compounds.
  • Cephalosporins such as cephalosporin C and 7-ACA are, after deacetylation in which 3-acetyl group is removed, served as semisynthetic intermediates for producing highly valuable cephalosporin antibiotics.
  • Deacetylation of cephalosporin may be performed by chemical or enzymatic processes.
  • the enzymatic process has advantages of mild reaction conditions of pH and temperature, and high yield (USP 3,304,236).
  • As an enzyme for this purpose two kinds of cephalosporin C deacetylase isolated from Bacillus subtilis have been reported, one of which has been introduced into a E. coli for mass production (EP 0454478A1, Applied and Environmental Microbiology, 1995, p 2224).
  • EP 0454478 A 1 is a giant enzyme of 280KDa consisting of eight monomers of 35KDa and shows a strong reactivity to the substrate such as cephalosporin C and 7-ACA.
  • 7'-substituted-CPC such as 2-memoxyh ⁇ m o-2-furylacetic cephalosporanic acid(MIFACA) which is precursor for cephalosporin antibiotics synthesis.
  • An object of the present invention is to provide a novel strain of Bacillus sp. capable of producing a cephalosporin C deacetylase of high enzyme activity.
  • Another object of the present invention is to provide a gene coding for the novel high activity cephalosporin C deacetylase.
  • Another object of the present invention is to provide an expression vector comprising the gene and a host strain transformed with the expression vector.
  • the present invention provides a method of deacetylating cephalosporin compounds which comprises contacting the compounds with the enzyme or the transformed strain.
  • Figure 1 shows the construction of expression vectors comprising the gene according to the present invention.
  • the present inventors isolated a novel strain of Bacillus sp. showing a potent cephalosporin C deacetylase activity from the soil in Ichon in Kyoungki-province. They also isolated and sequenced a novel gene coding for an active enzyme and cloned into an E. coli using vector systems. They studied biochemical properties of the enzyme coded thereby, which revealed that its properties are distinguished from those of the known deacetylation enzymes and showed a stronger affinity for substrate and a reactivity.
  • the present inventors further transformed a host strain with the recombinant vector comprising the gene.
  • the enzyme and transformed strain may be used to deacetylate cephalosporin compounds for giving useful intermediates for cephalosporin antibiotics synthesis according to the present invention.
  • the enzyme and strain may be immobilized on a proper carrier. The enzymatic process using the enzyme preparation or culture provides advantages that the number of steps can be reduced while the yield can be improved.
  • SEQ. ID. NO. 4 is an artificial sequence used as a Primer No. 1 for PCR.
  • SEQ. ID. NO. 4 is an artificial sequence used as a Primer No. 2 for PCR.
  • Example 1 Isolation of Bacillus sp. strain DS1152
  • a sample obtained from the soil in Ichon in Kyoungki-do, Korea was suspended in 0.9% of NaCl solution. After filtration, the supernatant was plated on nutrient agar and incubated at a temperature of about 30°C for 48 hours. The colonies on the plate were replicated on a solid LB(Luria-Beteani) medium containing 12mg of Fast blue RR salt and 20mg of ⁇ -naphthylacetate and incubated at a temperature of about 30°C for 24 hours. Thus, the strains forming a red-brown zone were selected. The selected strains were liquid cultivated in LB medium.
  • test sample was prepared by adding the supernatant as obtained above to 60mM of sodium phosphate buffer(pH 6.8) containing p- nitrophenylacetate(lmg/ml in methanol). The absorbance at 400nm was measured to select the strains having a high acetyl esterase activity(pNPA method).
  • a cell showing the highest enzyme activity was picked up and characterized. It was identified as Bacillus sp. and named DS 1152.
  • the Bacillus sp. strain DS 1152 was deposited on Korean Federation of Culture Collection in Seoul on April 11, 1998 and given accession number of KFCC 11026. The deposit was converted into one 5 under the Budapest Treaty on December 21 , 1998 and given accession number of KCCM- 10143 .
  • the Bacillus sp. strain DS 1152(KCCM-10143 ) can be grown in a solid LB medium at about 30°C for about 24 hours.
  • the biochemical characteristics of Bacillus sp. strain DS 1152(KCCM- 10143) are summarized in Table 2.
  • Isolation and purification of enzyme LB medium is placed in a 500ml flask and sterilization is carried out by autoclaving at 121°C for 20 minutes.
  • the flask was inoculated with Bacillus sp. strain DS1152 (KCCM -10143) and the resulting culture was grown at 30°C for 9 hours to be used as a seed culture.
  • Cephalosporin deacetylase was purified from the culture broth by following method.
  • the culture broth was centrifuged (5000 rpm X 30 minutes) to collect cells, which was suspended in 50 mM Tris/HCl buffer (pH 8.0) and disintegrated with an ultrasonic homogenizer. The resulting disintegrated cells were subjected to centrifugation (12,000 rpm X 30 rninutes) to remove insoluble fractions. Supernatant was subjected to fractional precipitation using 40 - 80% of saturated ammonium sulfate solution ((NH 4 ) 2 S0 4 ) to give a primarily purified protein. The resulting solution was subjected to ultrafiltration (MWCO 30 kDa) to remove salts and to concentrate.
  • MWCO 30 kDa saturated ammonium sulfate solution
  • resulting protein solution concentrate was loaded onto a column packed with DEAE-sepharose (Pharmacia) equilibrated with 10 mM Tris buffer (pH 8.0) at a flow rate of 2.0 ml/min and at an amount of 40 mg protein per ml of gel. Then, the column was washed with the equilibration buffer and eluted continuous concentration gradient manner using 0 - 300 mM NaCl. Most of cephalosporin deacetylase was eluted at 150 - 200 mM NaCl concentration.
  • Partially purified (95% purity) enzyme was ultraf ⁇ ltered against distilled water 7 to remove salts and freeze-dried.
  • the resulting enzyme was analyzed for its N- terminal 10 amino acid sequence by using Precise Protein Sequencing System (Applied Biosystems) following the standard analysis manual of the manufacturer.
  • the N-terminal 10 amino acid sequence is shown as SEQ. ID. NO. 1 in Sequence Listing.
  • the enzyme activity was measured by following the method described in EP 0,454,478 Al using 0.1M sodium phosphate buffer (pH 7.0). The activity was deterrnined that the amount of the enzyme required for deacetylating 1 mole of 7- AC A for 1 minute at 37°C is defined as one(l) unit. The freeze-dried enzyme was used by dissolving in a buffer.
  • the optimum pH of the enzyme was deterrnined. 7-ACA was used as a substrate, and the amounts of DACA produced and of the substrate consumed were measured by HPLC of the same conditions as above.
  • the enzyme shows the highest activity for pH range of 8.0 - 9.0.
  • Density gradient isoelectrofocusing was carried out with PhastSystemTM (Pharmacia Biotech) by following the Standard User's Manual to determine the isoelectric point(IP) of the enzyme. The experiment was carried out at a pH range from 3.0 to 9.0. Bovine serum albumin having LP of pH 4.7-4.9 is used as a standard. The band containing the enzyme was removed and dissolved into a distilled water to determine pH thereof. Thus, measured pH was 4.3.
  • the substrate reactivity of enzyme is defined as Michaelis constant (K which denotes a reaction speed of the enzyme.
  • K denotes a reaction speed of the enzyme.
  • the reaction is carried out by adding various concentrations of 7-ACA, cephalosporin C (CPC) or 2-methoxyimino-2- furylacetic cephalosporanic acid (MIFACA), as substrates, to 0.1M sodium phosphate buffer (pH 7.0) and allowed the resulting mixture to react at 37°C for 10 minutes, followed by HPLC.
  • K Michaelis constant
  • the results are shown in Table 3, which reveals that the enzyme shows the similar reactivities to all of the three cephalosporin derivatives. Table 3
  • MIFACA 2-methoxyi ⁇ mo-2-furylacetyl cephalosporanic acid
  • the strain of Bacillus sp. DS 1152 (KCCM-10143) was cultivated in LB medium at 30°C for 24 hours and the supernatant was subjected to centrifugation at 5000 rpm for 10 minutes to collect 4 g of cells.
  • the cells suspended in 20 mL of 20 mM Tris buffer (pH 8.0).
  • the resulting suspension was treated with 10 mL of 20% polyethylene glycol 8000 (PEG # 8000), 1 mL of lysozyme solution (100 mg/mL) and allowed to react at 37°C for 4 hours.
  • the resulting reaction mixture was subjected to centrifugation at 3500 rpm for 20 minutes to remove a supernatant, which was mixed with 20 mL of lOmM EDTA in 100 mM Tris buffer (pH 8.0). To the resulting mixture, 1 mL of
  • the resulting mixture was agitated under 15 mL of phenol chloroform/ isoamyl alcohol (25:24: 1) for 12 hours and subjected to centrifugation at 12000 rpm for 30 minutes to obtain a supernatant.
  • the supernatant was treated with 1.5 mL of acetic acid buffer (pH 5.2) and then 25 mL of cold ethanol and allowed to stand at -70°C for 15 minutes. Then, it was centrifuged at 12000 rpm for 10 minutes to remove a supernatant, and the resulting pellet was vacuum dried and dissolved into 500 ⁇ L of 1 mM EDTA in 10 mM Tris buffer (pH 8.0).
  • the transformed cells selected in the above (1) were streaked onto a petri dish to which were added 20 mg of alpha-naphthyl acetate in ethylene glycerol monomethyl ester and 12 mg of Fast blue RR salt in Tris-malate buffer (pH 7.6).
  • the strains forming a red-brown zone were selected by replica method.
  • the recombinant plasmid was isolated from the positive strains selected in the above (2) by using a plasmid isolation kit (Flex-prep kit, Pharmacia). Its restriction map shows that it is a 2.7 Kb DNA fragment having SphI restriction site at about 1.6
  • the 1.6 Kb fragment also showed the enzyme activity.
  • the 1.6 Kb fragment also showed the enzyme activity.
  • Kb fragment was digested with Sau3 Al and the resulting digestion products having
  • 0.4Kb, 0.8 Kb, 1.0 Kb or 1.3 Kb size were sub-cloned into s cloning vector, plasmid pUC18.
  • the nucleotide sequencing of these subclones were carried out with a sequencing kit (Cy5TM AutoRead TM sequencing kit ; Pharmacia) under the standard reaction conditions.
  • An automatic sequencer (ALF express automatic sequencer ;
  • Pharmacia is used to detei ine simultaneously the both of forward and reverse complementary nucleotide sequences of about 500 bases.
  • the nucleotide sequence of the total 1562 bp of the gene was deterrnined by using overlapping sequences and shown as SEQ. ID. NO. 2.
  • a structural gene segment of the full-length gene sequenced in the above (3) was determined based on the enzyme molecular weight (48 KDa for dimer and 24 KDa for subunit) measured in the purification of the enzyme, 10 N-terminal amino acids sequence (SEQ. ID. NO. 1) and open reading frame analysis.
  • the structural gene is between nucleotide No. 581 and nucleotide No. 1235, and its putative amino 12 acid sequence is shown as SEQ. ID. NO. 3.
  • the homology of the structural gene was searched, resulting in 93%.
  • Primer No. 1 (SEQ. ID. NO. 4) which has 21 bp with five Neol sites therein and Primer No. 2 (SEQ. ID. NO. 5) which has 22bp with three Hindlll sites therein were prepared and employed as PCR (Polymerase Chain Reaction) primers for amplifying cephalosporin deacetylase gene.
  • Plasmid pSPF1.6, Primer NO. 1, Primer No. 2 and Taq DNA polymerase were mixed and PCR was carried out for 30 cycles of 55°C 60 sec, 72°C 90 sec and 95°C 60 sec for each cycle to amplify the structural gene (654bp) of cephalosporin deacetylase.
  • the transformed strains of E. coli JM109 containing the recombinant plasmid 13 pDSTA654 (5.24Kb) or pDST654 (4.77 Kb) were cultivated in 100 mL of LB medium at 37°C for 12 hours and 0.5 mM of IPTG was added to induce the expression of the cephalosporin deacetylase gene.
  • the grown cells were collected by centrifugation at 5000 rpm for 10 minutes and suspended in 10 mL of 1 mM EDTA in 10 mM Tris-HCl buffer (pH 7.0). The resulting suspension was treated with an ultrasonicator for 10 seconds four times and centrifuged at 13000 rpm for 10 minutes to give a supernatant, which will be served as a material for gene expression evaluation.
  • the expression levels of the cephalosporin deacetylase gene (24 KDa) in the transformed E. coli JM109 containing pUC18 (Control), pDST654 or pDSTA654, or the strain Bacillus sp. DS1152 (KCCM- 10143) were evaluated by electrophoresis on SDS-polyacrylamide gel. Although, the number of copy of the gene amplified in the host slightly varies depending on the kind of the plasmid, both the plasmids show a high expression level.
  • the transformed strain E. coli JM109 (pDST654) (KCCM- 10140) was inoculated to 200 mL of seed culture medium containing glucose 0.2%, yeast extract 3% and NaCl 0.25% (pH 7.0) and cultivated at 28°C, 200 rpm for 12 hours.
  • seed culture was cultivated in 20 L of the same culture medium in a 50L fermentor at 28°C, 400 rpm and 1 v/v/m for 12 hours.
  • 10L of the same medium was additionally added to final concentrations of yeast extract 5.6%, NaCl 0.4% and glucose 3.4%.
  • 0.5 mM of IPTG was added to initiate the gene expression, followed by additional 4 hour fermentation.
  • the culture broth was centrifuged at 4000 rpm for 30 rninutes to harvest about 2 Kg of cells.
  • the cells (100 g, wet weight) were resuspended in 200 mL of solution of 0.9% NaCl in 0.2% benkol and stirred for 1 hour. The resulting suspension was centrifuged at 4000 rpm for 20 minutes to collect the cells, which were resuspended in 100 mL of 0.9% NaCl. A solution (800 mL) of 3% K-carrageenan, which was melted at 80°C, was cooled to 45°C and mixed with the cell suspension obtained above. The resulting mixture was immobilized as a thread shape in 0.3M KC1 solution. To improve the strength of the gel containing the cells, the gel was stored in 2L of solution of 85 mM of glutaraldehyde in 85 mM of hexamethylene diamine.
  • the cells (1 Kg) were suspended into a solution of 1 mM EDTA in 10 mM Tris-HCl buffer (pH 7.0) to a concentration of 20%, and disintegrated with a hydraulic cell disintegrator (Microfluidizer : Microfiuidics) at 1,000 psi. 20 mM MgCl 2 was added and treated with 1 U/mL of deoxyribonuclease I at room temperature for 1 hour to hydrolyze nucleic acids. The reaction solution was centrifuged at 4000 rpm for 30 rninutes to remove cell debris and cells. The resulting supernatant (4 L) was concentrated over microfilter and used as a material for enzyme immobilization.
  • a hydraulic cell disintegrator Microfluidizer : Microfiuidics
  • the enzyme immobilization was carried out by following the standard procedure of Eupergit-C (Roehm, Germany). That is, 500 mL of enzyme (titer 105 U/mL, total 25,000 units) was mixed with 100 g of Eupergit-C in 10M Tris-HCl buffer (pH 7.5) and allowed to stand at room temperature for 3 days. The resulting reaction mixture was filtered using 0. IM Tris-HCl (pH 7.5), washed and stored in a refrigerator.
  • reaction substrate (7-ACA) Fifty grams (50g) of reaction substrate (7-ACA) was dissolved in 1L of 100 mM sodium carbonate buffer (pH 7.5) and stirred with the enzyme (lOOg, 30 U/g) in a reactor.
  • 2N NH 4 OH was added to adjust the pH to about 7.8.
  • the reaction temperature was maintained at about 30°C and the reaction was stopped at the termination point of 2N NH 4 OH addition.
  • the reaction yield was 92 mole% by HPLC.
  • the same deacetylation except of using the immobilized cells (lOOg, 6.5 U/g bead) instead of immobilized enzyme showed the decreased reactivity due to the permeability of the substrate through the bead onto which the cells were immobilized. It took about 360 minutes to complete the deacetylation of 5% substrate and the reaction yield was 85 mole% by HPLC, which is slightly lower than that of the immobilized enzyme reaction.
  • the present invention allows a production of novel cephalosporin deacetylase by gene combination technology.
  • the enzyme is used to prepare deacetylated cephalosporin C, deacetylated 7-ACA and deacetylated MIFACA, all of them are intermediates for cephalosporin antibiotics synthesis.
  • the preparation process is more simple and gives a higher yield than the conventional chemical synthesis by inhibiting byproduct formation and intermediate decomposition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An isolated cephalosporin deacetylase derived from a strain of Bacillu sp. which (i) has an optimum pH between 8.0 and 9.0; (ii) has an optimum temperature of about 40 °C; and (iii) has an isoelectric point of about 4.3, and a DNA sequence which codes for the cephalosporin deacetylase are disclosed. An expression vector comprising the DNA sequence and transformed host strain carrying the vector are provided and used to deacetylate cephalosporin compounds to give useful intermediates for cephalosporin antibiotics synthesis.

Description

CEPHALOSPORIN DEACETYLASE, GENE CODING FOR IT,
AND PREPARATION METHOD OF DEACETYLATED
CEPHALOSPORIN COMPOUNDS USING IT
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
The present invention relates to a new enzyme, a gene coding for it and its use to produce cephalosporin compounds. More particularly, it relates to a new cephalosporin deacetylase, a gene coding for it, and its use to deacetylate cephalosporin C, 7-aminocephalosporanic acid (7-ACA) and 2-memoxyirnino-2- furylacetic cephalosporanic acid (MIFACA) to produce cephalosporin compounds.
2. DESCRIPTION OF THE PRIOR ARTS
Cephalosporins such as cephalosporin C and 7-ACA are, after deacetylation in which 3-acetyl group is removed, served as semisynthetic intermediates for producing highly valuable cephalosporin antibiotics.
Deacetylation of cephalosporin may be performed by chemical or enzymatic processes. The enzymatic process has advantages of mild reaction conditions of pH and temperature, and high yield (USP 3,304,236). As an enzyme for this purpose, two kinds of cephalosporin C deacetylase isolated from Bacillus subtilis have been reported, one of which has been introduced into a E. coli for mass production (EP 0454478A1, Applied and Environmental Microbiology, 1995, p 2224).
The enzyme disclosed in EP 0454478 A 1 is a giant enzyme of 280KDa consisting of eight monomers of 35KDa and shows a strong reactivity to the substrate such as cephalosporin C and 7-ACA. However, there has not been reported that it show reactivity to 7'-substituted-CPC such as 2-memoxyhτm o-2-furylacetic cephalosporanic acid(MIFACA) which is precursor for cephalosporin antibiotics synthesis.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a novel strain of Bacillus sp. capable of producing a cephalosporin C deacetylase of high enzyme activity.
Another object of the present invention is to provide a gene coding for the novel high activity cephalosporin C deacetylase.
Another object of the present invention is to provide an expression vector comprising the gene and a host strain transformed with the expression vector.
According to the present invention, it provides a method of deacetylating cephalosporin compounds which comprises contacting the compounds with the enzyme or the transformed strain.
The objects mentioned above, other features and applications of the present invention would be much more apparent by those of ordinary skills in the art from the following explanation in detail.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the construction of expression vectors comprising the gene according to the present invention.
DETAILED EXPLANATION OF THE INVENTION The present inventors isolated a novel strain of Bacillus sp. showing a potent cephalosporin C deacetylase activity from the soil in Ichon in Kyoungki-province. They also isolated and sequenced a novel gene coding for an active enzyme and cloned into an E. coli using vector systems. They studied biochemical properties of the enzyme coded thereby, which revealed that its properties are distinguished from those of the known deacetylation enzymes and showed a stronger affinity for substrate and a reactivity.
The present inventors further transformed a host strain with the recombinant vector comprising the gene. The enzyme and transformed strain may be used to deacetylate cephalosporin compounds for giving useful intermediates for cephalosporin antibiotics synthesis according to the present invention. The enzyme and strain may be immobilized on a proper carrier. The enzymatic process using the enzyme preparation or culture provides advantages that the number of steps can be reduced while the yield can be improved.
Free Text in Sequence Listing
SEQ. ID. NO. 4 is an artificial sequence used as a Primer No. 1 for PCR. SEQ. ID. NO. 4 is an artificial sequence used as a Primer No. 2 for PCR.
Examples
The present invention will be described in more detail by way of various Examples, which should not be construed to limit the scope of the present invention.
Example 1 : Isolation of Bacillus sp. strain DS1152
A sample obtained from the soil in Ichon in Kyoungki-do, Korea was suspended in 0.9% of NaCl solution. After filtration, the supernatant was plated on nutrient agar and incubated at a temperature of about 30°C for 48 hours. The colonies on the plate were replicated on a solid LB(Luria-Beteani) medium containing 12mg of Fast blue RR salt and 20mg of α-naphthylacetate and incubated at a temperature of about 30°C for 24 hours. Thus, the strains forming a red-brown zone were selected. The selected strains were liquid cultivated in LB medium. The cells collected from the medium were suspended in 60mM sodium phosphate buffer(pH 6.8) and disintegrated with an ultrasonic homogenizer. The disintegrated cells were subjected to centrifugation(12,000rpm X 20 rninutes) to obtain a supernatant. For measuring enzyme activity, test sample was prepared by adding the supernatant as obtained above to 60mM of sodium phosphate buffer(pH 6.8) containing p- nitrophenylacetate(lmg/ml in methanol). The absorbance at 400nm was measured to select the strains having a high acetyl esterase activity(pNPA method).
Further, the enzyme activity was measured by carrying out enzyme-reaction in lOmM of 7- AC A as a subatrate for 20 rninutes, and then quantitative analysis for deacetyl-7-ACA with HPLC. The activity of the selected strain was summarized in Table 1.
Table 1
pNPA method HPLC assay (μ mole deacetyl-pNPA/ (μ mole deacetyl-ACA/ mg protein/min) mg protein min)
Selected strain 1.033 0.46
Strain of 1.990 0.21
Figure imgf000006_0001
EP0454478A1
A cell showing the highest enzyme activity was picked up and characterized. It was identified as Bacillus sp. and named DS 1152. The Bacillus sp. strain DS 1152 was deposited on Korean Federation of Culture Collection in Seoul on April 11, 1998 and given accession number of KFCC 11026. The deposit was converted into one 5 under the Budapest Treaty on December 21 , 1998 and given accession number of KCCM- 10143 .
The Bacillus sp. strain DS 1152(KCCM-10143 ) can be grown in a solid LB medium at about 30°C for about 24 hours. The biochemical characteristics of Bacillus sp. strain DS 1152(KCCM- 10143) are summarized in Table 2.
Table 2
Characteristics
Shape Rod
Endospore formation Yes
Mobility Yes
Gram-stain Positive
Figure imgf000007_0001
Aerobic or anaerobic Aerobic
Example 2 : Isolation and characterization of enzyme
(1) Isolation and purification of enzyme LB medium is placed in a 500ml flask and sterilization is carried out by autoclaving at 121°C for 20 minutes. The flask was inoculated with Bacillus sp. strain DS1152 (KCCM -10143) and the resulting culture was grown at 30°C for 9 hours to be used as a seed culture.
Four liters of LB medium is placed in a 7.0 L flask and sterilization is carried out by autoclaving at 121°C for 20 minutes. The flask was inoculated with the seed culture of Bacillus sp. strain DS 1152 (KCCM-10143) obtained above to a final concentration of 1% and the cultivation was carried out at 30°C for 48 hours.
Cephalosporin deacetylase was purified from the culture broth by following method.
The culture broth was centrifuged (5000 rpm X 30 minutes) to collect cells, which was suspended in 50 mM Tris/HCl buffer (pH 8.0) and disintegrated with an ultrasonic homogenizer. The resulting disintegrated cells were subjected to centrifugation (12,000 rpm X 30 rninutes) to remove insoluble fractions. Supernatant was subjected to fractional precipitation using 40 - 80% of saturated ammonium sulfate solution ((NH4)2S04) to give a primarily purified protein. The resulting solution was subjected to ultrafiltration (MWCO 30 kDa) to remove salts and to concentrate. Thus resulting protein solution concentrate was loaded onto a column packed with DEAE-sepharose (Pharmacia) equilibrated with 10 mM Tris buffer (pH 8.0) at a flow rate of 2.0 ml/min and at an amount of 40 mg protein per ml of gel. Then, the column was washed with the equilibration buffer and eluted continuous concentration gradient manner using 0 - 300 mM NaCl. Most of cephalosporin deacetylase was eluted at 150 - 200 mM NaCl concentration. They are pooled and concentrated by subjecting to ultrafiltration (MWCO 30 kDa), and subjected to column chromatography over Sephacryl-S300 (Pharmacia) to obtain a purified desired protein. Its specific activity was measured using 7-ACA as a substrate and the result was 31 unit per mg protein.
(2) Measurement of molecular weight of enzyme
Gel chromatography was carried out on Sephacryl-S300 (Pharmacia) packed in a 1.6 X 100 cm column (Gel volume : 300 ml) to measure the molecular weight of the enzyme. Molecular weight marker proteins of 200 kDa, 150 kDa, 66 kDa, 29 kDa or 19.3 kDa (Sigma) were eluted using a buffer at a flow rate of 2.5 ml/min. The volume of the buffer used to elute the enzyme was compared with that for the marker proteins and the molecular weight of the enzyme was calculated using a standard curve. It was 48 kDa. In addition, the molecular weight of monomer was measured using 12% polyacryl and SDS-PAGE (Lammilis method). It was 24 kDa, indicating that the enzyme was a dimer consisting of two 24 kDa monomers.
(3) Sequencing of N-terminal of the enzyme
Partially purified (95% purity) enzyme was ultrafϊltered against distilled water 7 to remove salts and freeze-dried. The resulting enzyme was analyzed for its N- terminal 10 amino acid sequence by using Precise Protein Sequencing System (Applied Biosystems) following the standard analysis manual of the manufacturer. The N-terminal 10 amino acid sequence is shown as SEQ. ID. NO. 1 in Sequence Listing.
(4) Measurement of enzyme activity
The enzyme activity was measured by following the method described in EP 0,454,478 Al using 0.1M sodium phosphate buffer (pH 7.0). The activity was deterrnined that the amount of the enzyme required for deacetylating 1 mole of 7- AC A for 1 minute at 37°C is defined as one(l) unit. The freeze-dried enzyme was used by dissolving in a buffer. The quantitative analysis of deacetylated-7- aminocephalosporanic acid (DACA), a byproduct of 7-ACA deacetylation, was performed on HPLC under the following conditions: <HPLC conditions> Mobile phase : 50 mM (NH4)2HP04 / 55% CH3CN (pH 3.2)
Static phase : Alltech NH2
Column capacity : 4.6 X 250 mm
Flow rate : 0.6 miVmin
Wavelength : 254 nm Temperature : 45°C
(5) Determination of optimum pH
By using different buffers: 0.1M citrate buffer for pH 3.0 - 5.0; and 0.05M sodium phosphate + 0.05M citrate, followed by adjusting pH with NaOH, for pH 6.0
- 11.0, the optimum pH of the enzyme was deterrnined. 7-ACA was used as a substrate, and the amounts of DACA produced and of the substrate consumed were measured by HPLC of the same conditions as above. The enzyme shows the highest activity for pH range of 8.0 - 9.0.
(6) Determination of optimum reaction temperature
By using 0.1 M sodium phosphate buffer (pH 7.0), the optimum temperature was deterrnined. Enzyme activity was measured at an interval of 5°C at a range from 20 °C to 50° C using 7-ACA as a substrate. The measurement conditions are the same as those of HPLC in the above (4). The enzyme activity began to increase at 30
°C and showed the highest activity at 40 °C.
(7) Determination of Isoelectric Point of Enzyme
Density gradient isoelectrofocusing was carried out with PhastSystem™ (Pharmacia Biotech) by following the Standard User's Manual to determine the isoelectric point(IP) of the enzyme. The experiment was carried out at a pH range from 3.0 to 9.0. Bovine serum albumin having LP of pH 4.7-4.9 is used as a standard. The band containing the enzyme was removed and dissolved into a distilled water to determine pH thereof. Thus, measured pH was 4.3.
(8) Substrate Reactivity of Enzyme
The substrate reactivity of enzyme is defined as Michaelis constant (K which denotes a reaction speed of the enzyme. The reaction is carried out by adding various concentrations of 7-ACA, cephalosporin C (CPC) or 2-methoxyimino-2- furylacetic cephalosporanic acid (MIFACA), as substrates, to 0.1M sodium phosphate buffer (pH 7.0) and allowed the resulting mixture to react at 37°C for 10 minutes, followed by HPLC. By using Lineweaver-Burke formula, substrate reactivity was calculated. The results are shown in Table 3, which reveals that the enzyme shows the similar reactivities to all of the three cephalosporin derivatives. Table 3
Substrate Km(mM) Vmax (mole/min)
7-ACA 18.8 0.59
CPC *2 14.6 0.36
Figure imgf000011_0001
MIFACA *3 17.2 0.51
* 1 : 7-ACA = 7-aminocephalosporanic acid
* 2 : CPC = cephalosporin C
* 3 : MIFACA = 2-methoxyiπιmo-2-furylacetyl cephalosporanic acid
Further, various properties of the enzyme from the Strain disclosed in EP 0454478 A 1 were also determined, and summarized in Table 4 along with those of the enzyme according to the present invention.
Table 4
Properties \ Source Strain of Bacillus sp. DS 1152 EP 0454478 A 1 (KCCM- 10143 )
Molecular Weight 280 kDa 48 kDa
Structure Octamer Dimer
Optimum Temp. 55°C 40°C
Optimum pH 8.0 - 8.5 8.0 - 9.0
Isoelectric Point 5.3 4.3
Km (for 7-ACA ) 7.3 mM 18.8 mM
Km(for CPC*2) 24.3 mM 14.6 mM
Figure imgf000011_0002
Km(for MIFACA*3) - 17.2 mM
* 1 : 7-ACA = 7-aminocephalosporanic acid
* 2 : CPC = cephalosporin C * 3 : MIFACA = 2-methoxyinιmo-2-furylacetyl cephalosporanic acid 10
Example 2 : Separation and Sequencing of gene coding for the enzyme (1) DNA Isolation and Construction of Gene Library
The strain of Bacillus sp. DS 1152 (KCCM-10143) was cultivated in LB medium at 30°C for 24 hours and the supernatant was subjected to centrifugation at 5000 rpm for 10 minutes to collect 4 g of cells. The cells suspended in 20 mL of 20 mM Tris buffer (pH 8.0).
The resulting suspension was treated with 10 mL of 20% polyethylene glycol 8000 (PEG # 8000), 1 mL of lysozyme solution (100 mg/mL) and allowed to react at 37°C for 4 hours. The resulting reaction mixture was subjected to centrifugation at 3500 rpm for 20 minutes to remove a supernatant, which was mixed with 20 mL of lOmM EDTA in 100 mM Tris buffer (pH 8.0). To the resulting mixture, 1 mL of
25% SDS was added and mixed well at 37°C for 1 hour to give a suspension. A solution (200 L) of proteinase K (20 mg/mL) was added and reacted for 4 hours.
The resulting mixture was agitated under 15 mL of phenol chloroform/ isoamyl alcohol (25:24: 1) for 12 hours and subjected to centrifugation at 12000 rpm for 30 minutes to obtain a supernatant. The supernatant was treated with 1.5 mL of acetic acid buffer (pH 5.2) and then 25 mL of cold ethanol and allowed to stand at -70°C for 15 minutes. Then, it was centrifuged at 12000 rpm for 10 minutes to remove a supernatant, and the resulting pellet was vacuum dried and dissolved into 500 μL of 1 mM EDTA in 10 mM Tris buffer (pH 8.0).
Thus isolated DNA was partially digested with Sau3Al and subjected to sucrose density gradient ultracentrifugation at 25000 rpm for 24 hours to fractionize the digestion fragments depending on their sizes. The fragments was precipitated under 70% ethanol and vacuum dried to give DNA fragments of 2 - 6 Kb. The DNA fragments were ligated to pUC18 vector which was treated with
BamHI, and the resulting recombinant pUC18 vector was transformed into the strain of E. coli JM109. The transformed cells were grown in a petri dish containing 50 μg/mL of ampicillin to select grown strains. 1 1
(2) Selection of Acetyl esterase-Positive Strains
To select the strains having Acetyl esterase activity, the transformed cells selected in the above (1) were streaked onto a petri dish to which were added 20 mg of alpha-naphthyl acetate in ethylene glycerol monomethyl ester and 12 mg of Fast blue RR salt in Tris-malate buffer (pH 7.6). The strains forming a red-brown zone were selected by replica method.
(3) Nucleotide Sequencing of Positive Clones
The recombinant plasmid was isolated from the positive strains selected in the above (2) by using a plasmid isolation kit (Flex-prep kit, Pharmacia). Its restriction map shows that it is a 2.7 Kb DNA fragment having SphI restriction site at about 1.6
Kb site (pSPFl.6). The 1.6 Kb fragment also showed the enzyme activity. The 1.6
Kb fragment was digested with Sau3 Al and the resulting digestion products having
0.4Kb, 0.8 Kb, 1.0 Kb or 1.3 Kb size were sub-cloned into s cloning vector, plasmid pUC18. The nucleotide sequencing of these subclones were carried out with a sequencing kit (Cy5™ AutoRead ™ sequencing kit ; Pharmacia) under the standard reaction conditions. An automatic sequencer (ALF express automatic sequencer ;
Pharmacia) is used to detei ine simultaneously the both of forward and reverse complementary nucleotide sequences of about 500 bases. The nucleotide sequence of the total 1562 bp of the gene was deterrnined by using overlapping sequences and shown as SEQ. ID. NO. 2.
(4) Gene Probing
A structural gene segment of the full-length gene sequenced in the above (3) was determined based on the enzyme molecular weight (48 KDa for dimer and 24 KDa for subunit) measured in the purification of the enzyme, 10 N-terminal amino acids sequence (SEQ. ID. NO. 1) and open reading frame analysis. The structural gene is between nucleotide No. 581 and nucleotide No. 1235, and its putative amino 12 acid sequence is shown as SEQ. ID. NO. 3. The homology of the structural gene was searched, resulting in 93%.
Example 3 : Gene Expression (1) PCR Amplification of Gene
Two oligonucleotide primers: Primer No. 1 (SEQ. ID. NO. 4) which has 21 bp with five Neol sites therein and Primer No. 2 (SEQ. ID. NO. 5) which has 22bp with three Hindlll sites therein were prepared and employed as PCR (Polymerase Chain Reaction) primers for amplifying cephalosporin deacetylase gene. Plasmid pSPF1.6, Primer NO. 1, Primer No. 2 and Taq DNA polymerase were mixed and PCR was carried out for 30 cycles of 55°C 60 sec, 72°C 90 sec and 95°C 60 sec for each cycle to amplify the structural gene (654bp) of cephalosporin deacetylase.
(2) Construction of Expression Vectors The amplified gene was digested with Neol and Hindlll, and ligated into pKK223-3 (AmpR+, Pharmacia) digested with Smal and Hindlll, or pTrc99A (AmpR+, Pharmacia) digested with Neol and Hindlll to give pDSTA654 (5.24 Kb) or pDST654(4.77 Kb), respectively. The recombinant plasmids were transformed into E. coli JM109 and the transformed strain containing pDST654 was deposited with Korean Federation of Culture Collections on April 24, 1998 and given accession number of KFCC-11029. This deposit was converted into one under Budapest Treaty on November 11, 1998 and assigned an accession number of KCCM- 10140.
The flow of constructing the expression vectors pDSTA654 (5.24 Kb) and pDST654(4.77 Kb) is shown in Figure 1.
(3) Gene Expression
The transformed strains of E. coli JM109 containing the recombinant plasmid 13 pDSTA654 (5.24Kb) or pDST654 (4.77 Kb) were cultivated in 100 mL of LB medium at 37°C for 12 hours and 0.5 mM of IPTG was added to induce the expression of the cephalosporin deacetylase gene. The grown cells were collected by centrifugation at 5000 rpm for 10 minutes and suspended in 10 mL of 1 mM EDTA in 10 mM Tris-HCl buffer (pH 7.0). The resulting suspension was treated with an ultrasonicator for 10 seconds four times and centrifuged at 13000 rpm for 10 minutes to give a supernatant, which will be served as a material for gene expression evaluation.
The expression levels of the cephalosporin deacetylase gene (24 KDa) in the transformed E. coli JM109 containing pUC18 (Control), pDST654 or pDSTA654, or the strain Bacillus sp. DS1152 (KCCM- 10143) were evaluated by electrophoresis on SDS-polyacrylamide gel. Although, the number of copy of the gene amplified in the host slightly varies depending on the kind of the plasmid, both the plasmids show a high expression level. 7- AC A, as a substrate, was dissolved in 10 mM Tris-HCl buffer (pH 8.0) to a concentration of 5 mg/mL and 7- AC A was added to 50 mM Tris-HCl buffer (pH 7.0) to a final concentration of 2.5 mg/mL. The resulting mixture was allowed to react at 30°C for 30 minutes and the amount of deacetylated 7-ACA produced was analyzed by HPLC. The amount of protein from cell homogenate was measured by Bradford Assay by comparing with standard protein level, and the specific enzyme production titer expressed as μmole of deacetylated 7-ACA produced by one(l) mg of protein for 1 minute was shown in Table 5. 14
Table 5
Specific Enzyme
Host Cell Plasmid Inducer Production Titer
(μmole deacetylated 7-
ACA/mg protein/min) pUC18 - 0.05
E. coli JM109 pDST654 0.5 mM IPTG 4.72 pDSTA654 0.5 mM IPTG 3.20
Bacillus sp. - - 0.46
Figure imgf000016_0001
DS 1152
Example 4 : Fermentation and Immobilization (1) Fermentation
The transformed strain E. coli JM109 (pDST654) (KCCM- 10140) was inoculated to 200 mL of seed culture medium containing glucose 0.2%, yeast extract 3% and NaCl 0.25% (pH 7.0) and cultivated at 28°C, 200 rpm for 12 hours. Thus obtained seed culture was cultivated in 20 L of the same culture medium in a 50L fermentor at 28°C, 400 rpm and 1 v/v/m for 12 hours. At the point of sugar depletion, 10L of the same medium was additionally added to final concentrations of yeast extract 5.6%, NaCl 0.4% and glucose 3.4%. When the fermentation reached to log phase, 0.5 mM of IPTG was added to initiate the gene expression, followed by additional 4 hour fermentation. The culture broth was centrifuged at 4000 rpm for 30 rninutes to harvest about 2 Kg of cells.
(2) Cell Immobilization
The cells (100 g, wet weight) were resuspended in 200 mL of solution of 0.9% NaCl in 0.2% benkol and stirred for 1 hour. The resulting suspension was centrifuged at 4000 rpm for 20 minutes to collect the cells, which were resuspended in 100 mL of 0.9% NaCl. A solution (800 mL) of 3% K-carrageenan, which was melted at 80°C, was cooled to 45°C and mixed with the cell suspension obtained above. The resulting mixture was immobilized as a thread shape in 0.3M KC1 solution. To improve the strength of the gel containing the cells, the gel was stored in 2L of solution of 85 mM of glutaraldehyde in 85 mM of hexamethylene diamine.
(3) Enzyme Immobilization
The cells (1 Kg) were suspended into a solution of 1 mM EDTA in 10 mM Tris-HCl buffer (pH 7.0) to a concentration of 20%, and disintegrated with a hydraulic cell disintegrator (Microfluidizer : Microfiuidics) at 1,000 psi. 20 mM MgCl2 was added and treated with 1 U/mL of deoxyribonuclease I at room temperature for 1 hour to hydrolyze nucleic acids. The reaction solution was centrifuged at 4000 rpm for 30 rninutes to remove cell debris and cells. The resulting supernatant (4 L) was concentrated over microfilter and used as a material for enzyme immobilization.
The enzyme immobilization was carried out by following the standard procedure of Eupergit-C (Roehm, Germany). That is, 500 mL of enzyme (titer 105 U/mL, total 25,000 units) was mixed with 100 g of Eupergit-C in 10M Tris-HCl buffer (pH 7.5) and allowed to stand at room temperature for 3 days. The resulting reaction mixture was filtered using 0. IM Tris-HCl (pH 7.5), washed and stored in a refrigerator.
Example 5 : Deacetylation by Immobilized Enzyme or Cell
The reaction scheme of deacetylation by cephalosporin deacetylase according to the present invention is as follows: R - Rl : H- 7-Aminocephalosporanic acid O
OAc
Figure imgf000018_0001
R2 : H2N-CH-(CH2)3- C- Cephalosporin C
COOH CO2H
Cephalosporin R3
11 Deacetylase ~v O
C- C 2-Methoxyimino-2-furyl- " acetic cephalosporanic acid
O NOCH3 (MIFACA)
R-NH
CH3COOH
// N\ ^\^ OH O Υ
COOH
Fifty grams (50g) of reaction substrate (7-ACA) was dissolved in 1L of 100 mM sodium carbonate buffer (pH 7.5) and stirred with the enzyme (lOOg, 30 U/g) in a reactor.
To avoid the decrease of pH of the reaction mixture due to acetic acid generated during deacetylation, 2N NH4OH was added to adjust the pH to about 7.8. The reaction temperature was maintained at about 30°C and the reaction was stopped at the termination point of 2N NH4OH addition.
It took about 90 minutes to complete the deacetylation of 5% substrate and the reaction yield was 92 mole% by HPLC. The same deacetylation except of using the immobilized cells (lOOg, 6.5 U/g bead) instead of immobilized enzyme showed the decreased reactivity due to the permeability of the substrate through the bead onto which the cells were immobilized. It took about 360 minutes to complete the deacetylation of 5% substrate and the reaction yield was 85 mole% by HPLC, which is slightly lower than that of the immobilized enzyme reaction. As described above, the present invention allows a production of novel cephalosporin deacetylase by gene combination technology. The enzyme is used to prepare deacetylated cephalosporin C, deacetylated 7-ACA and deacetylated MIFACA, all of them are intermediates for cephalosporin antibiotics synthesis. The preparation process is more simple and gives a higher yield than the conventional chemical synthesis by inhibiting byproduct formation and intermediate decomposition.
Although preferred embodiments of the present invention have been described in detail herein above, it should be clearly understood that many variations and/or modifications of the basic inventive concepts herein taught which may appear to those skilled in the art will still fall within the spirit and scope of the present invention as defined in the appended claims.

Claims

1. An isolated cephalosporin deacetylase derived from a strain of Bacillu sp. which: (I) has an optimum pH between 8.0 and 9.0;
(ii) has an optimum temperature of about 40°C; and (iii) has an isoelectric point of about 4.3.
2. A cephalosporin deacetylase according to Claim 1 which is a dimer having a molecular weight of about 48Kda.
3. A cephalosporin deacetylase according to Claim 1, wherein the strain is Bacillus sp. DS 1152 (KCCM- 10143 ).
4. A cephalosporin deacetylase according to claim 1 which has an N-terminal sequence : SEQ. ID. NO. 1.
5. A DNA sequence which codes for a cephalosporin deacetylase according to claim 1 and comprises a fragment between nucleotide No. 581 and nucleotide No. 1235 in SEQ. ID. NO. 1.
6. A DNA sequence according to claim 5 which is shown as SEQ. ID. NO. 2.
7. An expression vector comprising a DNA sequence according to claim 5.
8. A host strain transformed with an expression vector according to claim 7.
9. A transformed strain according to claim 8, wherein host strain is E. coli JM109. 19
10. A transformed strain according to claim 9 which is a strain of E. coli JM109 (pDST654) (KCCM- 10140).
11. An isolated strain of Bacillus sp. which has the same biochemical characteristics as those of Bacillus sp. DS1152 (KCCM-10143).
12. A method of deacetylating cephalosporin compounds, comprising contacting the compounds with an enzyme according to claim 1 or a transformed strain according to claim 8.
13. A method according to claim 12, wherein said enzyme or strain is immobilized on a carrier.
PCT/KR1998/000487 1998-04-24 1998-12-30 Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it WO1999055881A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1998/14790 1998-04-24
KR1019980014790A KR100270508B1 (en) 1998-04-24 1998-04-24 Novel cephalosporin diacetylase gene and protein production method using the same

Publications (1)

Publication Number Publication Date
WO1999055881A1 true WO1999055881A1 (en) 1999-11-04

Family

ID=19536687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1998/000487 WO1999055881A1 (en) 1998-04-24 1998-12-30 Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it

Country Status (2)

Country Link
KR (1) KR100270508B1 (en)
WO (1) WO1999055881A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061767A1 (en) * 1999-04-09 2000-10-19 Antibioticos, S.A.U. Extracellular protease from $i(acremonium chrysogenum) with cpc-acetyl hydrolase activity and its utilization in the synthesis of deacetylated derivatives of cephalosporin c and inactivation of the gene for increasing production of cephalosporin
WO2009013611A3 (en) * 2007-07-26 2009-04-02 Orchid Chemicals & Pharm Ltd Modified esterase and its applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454478A1 (en) * 1990-04-27 1991-10-30 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI &amp; CO. LTD. Cephalosporin acetylhydrolase gene and protein encoded by said gene
JPH0453499A (en) * 1990-06-19 1992-02-21 Shionogi & Co Ltd Production of deacetyl-7-aminocephalosphoranic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454478A1 (en) * 1990-04-27 1991-10-30 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI &amp; CO. LTD. Cephalosporin acetylhydrolase gene and protein encoded by said gene
JPH0453499A (en) * 1990-06-19 1992-02-21 Shionogi & Co Ltd Production of deacetyl-7-aminocephalosphoranic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 16, no. 244 1992 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061767A1 (en) * 1999-04-09 2000-10-19 Antibioticos, S.A.U. Extracellular protease from $i(acremonium chrysogenum) with cpc-acetyl hydrolase activity and its utilization in the synthesis of deacetylated derivatives of cephalosporin c and inactivation of the gene for increasing production of cephalosporin
US6815189B1 (en) 1999-04-09 2004-11-09 Antibiotics, S.A.U. Gene from acremonium chrysogenum encoding a protein with cephalosporin C acetylhydrolase activity and methods of use of such gene
WO2009013611A3 (en) * 2007-07-26 2009-04-02 Orchid Chemicals & Pharm Ltd Modified esterase and its applications

Also Published As

Publication number Publication date
KR19990081077A (en) 1999-11-15
KR100270508B1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
EP0454478B1 (en) Cephalosporin acetylhydrolase gene and protein encoded by said gene
FI108148B (en) New bioprocess for the preparation of 7-ADCA
JP4561010B2 (en) DNA encoding D-hydantoin hydrolase, DNA encoding N-carbamyl-D-amino acid hydrolase, recombinant DNA containing the gene, cells transformed with the recombinant DNA, and production of proteins using the transformed cells Method and method for producing D-amino acid
EP1142997B1 (en) Novel rhodococcus, rhodococcus-origin nitrilase gene, nitrilehydratase gene and amidase gene and process for producing carboxylic acids by using the same
US6465233B1 (en) Nucleic acid molecule encoding a cephalosporin acetylesterase
KR20140094150A (en) A mutant enzyme for production of cephalosporin antibiotics
US5114853A (en) Recombinant dna, transformant containing said dna, and process for preparing heat-stable glucose dehydrogenase by use of said transformant
CA2183632A1 (en) Process for producing 2-keto-l-gulonic acid
CN110129305B (en) Cephalosporin C acylase mutant for preparing 7-ACA
CN111172142A (en) Cephalosporin C acylase mutant with high thermal stability
JP4529338B2 (en) DNA encoding hydantoinase, DNA encoding N-carbamyl-L-amino acid hydrolase, recombinant DNA, transformed cell, protein production method and optically active amino acid production method
JP4561009B2 (en) DNA encoding D-hydantoin hydrolase, DNA encoding N-carbamyl-D-amino acid hydrolase, recombinant DNA containing the gene, cells transformed with the recombinant DNA, and production of proteins using the transformed cells Method and method for producing D-amino acid
WO1999055881A1 (en) Cephalosporin deacetylase, gene coding for it, and preparation method of deacetylated cephalosporin compounds using it
EP0513806B1 (en) Esterase genes, esterase, recombinant plasmids and transformants containing the recombinant plasmid and methods of producing optically active carboxylic acids and their enantiomeric esters using said transformants
JP3658323B2 (en) Trehalose synthase protein, gene, plasmid, microorganism, and method for producing trehalose
WO2002099109A1 (en) Novel polypeptide, dna encoding the polypeptide and use thereof
US5766871A (en) Screening and characterization of glutaryl-7-aminocephalosporanic acid acylase
AU2002254519A1 (en) D-hydantoinase from ochrobactrum anthropi
WO2002081626A2 (en) D-hydantoinase from ochrobactrum anthropi
JP2712331B2 (en) Acylamino acid racemase, its production and use
JPH0898683A (en) 7-aminocephalosporanic acid esterase
JP4415247B2 (en) Novel glycerol kinase, gene and method for producing glycerol kinase using the gene
JPH10262674A (en) Gene coding for alkaline phosphatase
KR19980070317A (en) Polyhydroxyalkanoate degrading enzyme and preparation method thereof
JPH08205864A (en) New cephalosporin c acylase and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase